公开(公告)号：US09480712B2

公开(公告)日：2016-11-01

申请号：US14514137

申请日：2014-10-14

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Ya-Chin Lo ,  Hsiang-Fa Liang ,  Ming-Cheng Wei ,  Maggie J. M. Lu ,  Min-Ying Lin ,  Chih-Peng Liu ,  Chun-Min Liu ,  Hsiang-Wen Tseng ,  Tse-Min Teng ,  Jui-Hsiang Chen ,  Yi-Man Chou ,  Yi-Ting Hsieh ,  Chia-Mu Tu

IPC: C08B37/08 ,  A61K47/48 ,  A61K31/704 ,  A61K31/4745 ,  A61K31/7036 ,  A61K33/24 ,  A61K45/06 ,  A61K31/4172 ,  A61K31/555 ,  A61K31/728

CPC classification number: A61K33/24 ,  A61K31/4172 ,  A61K31/4745 ,  A61K31/555 ,  A61K31/7036 ,  A61K31/704 ,  A61K31/728 ,  A61K45/06 ,  A61K47/542 ,  A61K47/61 ,  A61K47/6921 ,  A61K2300/00

Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.

Abstract translation: 本公开提供了一种生物医学组合物，其包括：透明质酸; 修饰的组氨酸 和聚合物或C 4 -C 20烷烃，其中将经修饰的组氨酸和聚合物或C 4 -C 20烷烃接枝至透明质酸的至少一个伯羟基，以使透明质酸形成透明质酸衍生物，其中接枝率 的改性组氨酸约为1-100％，聚合物或C4-C20烷烃的接枝率约为0-40％。

公开(公告)号：US09408917B2

公开(公告)日：2016-08-09

申请号：US13926363

申请日：2013-06-25

Applicant: Industrial Technology Research Institute

Inventor： Maggie J. M. Lu ,  Yu-Wen Lo ,  Chih-Peng Liu ,  Chia-Wen Huang ,  Shuen-Hsiang Chou ,  Po-Hung Lai ,  Tsan-Lin Hu ,  Min-Ying Lin ,  Chia-Mu Tu

IPC: A61K47/36 ,  A61K9/00 ,  A61K9/127

CPC classification number: A61K47/36 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/127

Abstract: The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.

Abstract translation: 本公开提供药物组合物。 药物组合物包括具有棕榈酰基团的壳聚糖和活性剂。 根据另一个实施方案，药物组合物可以进一步包括胶凝加速剂。 根据本公开的实施方案，本公开的活性剂可以以纳米药物，脂质体，胶束或微粒的形式施用。

公开(公告)号：US09757330B2

公开(公告)日：2017-09-12

申请号：US14488431

申请日：2014-09-17

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Felice Cheng ,  Maggie J. M. Lu ,  Yi-Ju Ko ,  Min-Ying Lin ,  Shuen-Hsiang Chou

IPC: A61K38/00 ,  C07K16/00 ,  A61K9/00 ,  A61K47/36 ,  A61K31/00

CPC classification number: A61K9/0048 ,  A61K9/0024 ,  A61K31/00 ,  A61K47/36

Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.